Precision Acupuncture in the Treatment of Peripheral Neuropathy After Taxanes Chemotherapy in Breast Cancer
Breast Cancer
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring acupuncture, breast cancer, peripheral neuropathy, taxane chemotherapy
Eligibility Criteria
Inclusion Criteria:
- The patient was at least 18 years old and had reported grade 1 or higher neuropathic symptoms for more than 2 weeks;
- Patients were screened for eligibility by the investigator prior to enrollment, including verification of baseline neuropathic symptoms.
- Patients had a diagnosis of stage I, II, or IIIA breast cancer;
- Have completed at least 2 weeks of chemotherapy;
- Higher scores indicate more severe symptoms;
- Voluntarily participate in the clinical trial and sign the informed consent form after informed consent (patients voluntarily accept the treatment and give informed consent);
- Eastern Cooperative Oncology Group (ECOG ) score of physical condition (0-1);
- Patients with previous local recurrence were eligible;
- The basic indexes were consistent, and the blood routine and ECG were normal.
Exclusion Criteria:
- patients with needle phobia;
- Low platelet count (<50 000); co-morbidity with a bleeding disorder; comorbidity with thyroid dysfunction; pregnancy; haemoglobin levels <10 g/dl and haematocrit <30; anaemia on active pharmacological treatment or receiving blood transfusion or steroids;
- having metastatic or recurrent disease, history of preexisting peripheral neuropa- thy prior to chemotherapy, uncontrolled seizure disorder, unstable cardiac disease or myocardial infarction within 6 months prior to study entry;
- Being pregnant or nursing, or having used acupuncture for peripheral neuropathy within 6 months prior to study entry;
- Life expectancy <6 months;
- Lymphedema of limbs;
Sites / Locations
- Affiliated Hospital of Qinghai UniversityRecruiting
Arms of the Study
Arm 1
Experimental
Acupuncture group
This is a one-arm study. Breast cancer patients with peripheral neuropathy were measured using the FACT/ GOG-Ntx and EORTC QLQ-CIPN20 scales. Our clinical study included breast cancer patients diagnosed with peripheral neurotoxicity caused by taxanes-based drugs who would receive acupuncture treatment. Neurotoxicity was identified based on NCI-CTCAE 5.0 for daily or almost daily numbness in the hands and feet, tingling, and other symptoms of peripheral neuropathy over the past two to three weeks. Blood samples were collected from patients to detect SNP associated with neurotoxicity.